GlassScriptPhysician profile
Michael W Lansing
NPI 1962483230
$84,693.60
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $20K · 2021: $2,638.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $82,936.69 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.05 | 2019-2021 | |
| Insmed, INC. | $270.32 | 2019-2020 | |
| Grifols USA, LLC | $257.14 | 2019-2021 | |
| Mylan Specialty L.P. | $239.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $176.92 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $62.95 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $46.23 | 2019-2020 | |
| Genentech USA, INC. | $38.72 | 2019 | |
| Resmed Corp | $37.77 | 2019 | |
| Novo Nordisk INC | $32.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.77 | 2019 | |
| Neos Therapeutics, LP | $24.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.39 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.45 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.25 | 2019 | |
| Amgen INC. | $18.84 | 2019 | |
| Fisher & Paykel Healthcare INC | $15.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lansing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.